ClinicalTrials.gg
Not yet recruitingNCT07942142Updated Nov 17, 2026

A Registry Evaluating the Real-World Clinical Use, Procedural Characteristics, Safety, and Effectiveness of the VARIPULSE™ PRO Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation

An observational study in Atrial Fibrillation (AF), sponsored by Waterloo Regional Health Network. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Waterloo Regional Health Network · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn more about how safe and how well a treatment called catheter ablation works to treat atrial fibrillation (AF) when the VARIPULSE system is used.

This study collects information from people receiving this treatment as part of their usual medical care. Researchers want to understand how the procedure is used in everyday practice.

The secondary purpose of this study is to create a registry to collect data to be used for future research.

02

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

03

In context

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.

This study's planned enrollment of 500 is above the median of 300 across 1,404 observational studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

This is the only study on the registry with Waterloo Regional Health Network as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing catheter ablation for atrial fibrillation using the VARIPULSE PRO platform.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic paroxysmal atrial fibrillation (AF episode that terminates spontaneously within 7 days)
  • Indicated for catheter ablation in the opinion of the investigator
  • De Novo and redo AF ablation procedures
  • Age > 18 years
  • Will be treated with Biosense Webster Inc. Ablation Technologies
  • All AF ablations performed with BWI technology.
  • Able and willing to participate in baseline and follow-up evaluations.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Persistent atrial fibrillation
  • Non-AF ablation procedures without AF treatment
  • Inability to provide
  • Enrolled in an drug or device clinical trial, or any trial that dictates the treatment plan
  • In the opinion of the investigator, any known to an ablation procedure
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • ProcedureCatheter ablation procedure to treat atrial fibrillation (AF)

    Catheter ablation procedure to treat atrial fibrillation (AF) using the VARIPULSE™ PRO system.

06

What researchers measure

Primary outcomes

  1. Procedural Characteristics and Lesion Delivery Patterns of VARIPULSE™-Based Atrial Fibrillation Ablation Using the PRO Sequence

    To characterize real-world procedural practices associated with VARIPULSE™ pulsed field ablation using the PRO sequence in patients undergoing atrial fibrillation ablation. Measures will include total number of PFA applications, number of applications delivered per pulmonary vein, lesion distribution within the left atrium, completeness of pulmonary vein lesion sets, and use of adjunctive ablation strategies. Additional lesion sets, including posterior wall isolation, roof line, mitral isthmus, cavotricuspid isthmus, anterior wall and other mapped atrial tachycardia targets, will also be documented.

    Time frame: During the index ablation procedure.

  2. Procedural Workflow and Efficiency Metrics

    To evaluate procedural workflow, duration and resource utilization during VARIPULSE™-based atrial fibrillation ablation. Measures will include total procedure duration, left atrial dwell time, fluoroscopy time, radiation dose, number of transseptal punctures, total ablation time, and use of adjunctive ablation technologies, including supplemental radiofrequency ablation. Additional procedural characteristics will include anesthesia type, ventilation strategy, intracardiac echocardiography utilization, electroanatomical mapping workflow and left atrial voltage map acquisition.

    Time frame: During the index ablation procedure.

  3. Pulmonary Vein Lesion Delivery and Isolation Characteristics

    To characterize pulmonary vein lesion delivery and isolation efficiency during VARIPULSE™ PFA procedures using the PRO sequence. Measures will include total lesions delivered, number of lesions per pulmonary vein, completeness of concentric lesion rings, number of lesions required to achieve pulmonary vein isolation, and pulmonary vein isolation transpired time. Pulmonary vein isolation transpired time is defined as the interval between the first and final pulmonary vein ablation applications, excluding subsequent touch-up lesions performed following additional linear lesion sets.

    Time frame: During the index ablation procedure.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 12 months is below that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Feb 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942142
Lead sponsor
Waterloo Regional Health Network
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Carla Girolametto
Contact
carla.girolametto@wrhn.ca
5194974300

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion